Document is current
Any future updates will be listed below
-
Authors
Guillory, Sylvia B.
Baskett, Victoria Z.
Grosman, Hannah E.
McLaughlin, Christopher S.
Isenstein, Emily L.
Wilkinson, Emma
Weissman, Jordana
Britvan, Bari
Trelles, M. Pilar
Halpern, Danielle B.
Buxbaum, Joseph D.
Siper, Paige M.
Wang, A. Ting
Kolevzon, Alexander
Foss-Feig, Jennifer H. https://orcid.org/0000-0002-1491-8248
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (TL1TR001434)
National Institute of Neurological Disorders and Stroke (U54NS092090)
Beatrice and Samuel A. Seaver Foundation
- License Information
-
More Information
Article History
Received: 5 June 2020
Accepted: 14 October 2021
First Online: 4 December 2021
Declarations
:
: This study was approved by the Mount Sinai Program for the Protection of Human Subjects. All participants received informed consent about the purpose of the research project, possible risks and benefits, and the contact information of the researcher and the institutional program for the Protection of Human Subjects Office.
: Not applicable.
: AK receives research support from AMO Pharma and consults to Acadia, Ovid Therapeutics, and sema4. All other authors declare that they have no competing interests.
